GT Biopharma

GT Biopharma Current Liabilities

The Current Liabilities of GT Biopharma (GTBP) as of Oct 22, 2026 is 2.32 M USD. In the previous year, Current Liabilities was 7.70 M USD — a change of -69.88% (lower).

Current Liabilities

2.32 MUSD

YoY

-69.88%

Last updated:

Current Liabilities of GT Biopharma is 2025 2.32 M USD. Current Liabilities of GT Biopharma was 2024 7.70 M USD. It decreases by -69.88% lower compared to the previous year.

The GT Biopharma Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
26.16 M USD
Jan 1, 2019
37.44 M USD
Jan 1, 2020
61.40 M USD
Jan 1, 2021
10.26 M USD
Jan 1, 2022
6.72 M USD
Jan 1, 2023
7.89 M USD
Jan 1, 2024
7.70 M USD
Jan 1, 2025
2.32 M USD
The GT Biopharma Current Liabilities history
YEARCurrent LiabilitiesYoY
2.32 MUSD-69.88%
7.70 MUSD-2.37%
7.89 MUSD+17.40%
6.72 MUSD-34.53%
10.26 MUSD-83.29%
61.40 MUSD+63.98%
37.44 MUSD+43.14%
26.16 MUSD+840.56%
2.78 MUSD-90.51%
29.30 MUSD-48.35%
56.73 MUSD+82.79%
31.04 MUSD+229.53%
9.42 MUSD+8.77%
8.66 MUSD+5.47%
8.21 MUSD+35.28%
6.07 MUSD-11.52%
6.86 MUSD+30.05%
5.27 MUSD+25.69%
4.20 MUSD-45.17%
7.65 MUSD+63.00%
4.70 MUSD+33.80%
3.51 MUSD+147.64%
1.42 MUSD+37.97%
1.03 MUSD-33.18%
1.54 MUSD-16.56%
1.84 MUSD-33.98%
2.79 MUSD-13.11%
3.21 MUSD-42.39%
5.57 MUSD+31.74%
4.23 MUSD-21.65%
5.40 MUSD+3.83%
5.20 MUSD+1,340.72%
361,000.00USD-45.96%
668,000.00USD+234.00%
200,000.00USD0.00%
200,000.00USD-60.00%
500,000.00USD+66.67%
300,000.00USD+50.00%
200,000.00USD-67.95%
624,000.00USD+313.25%
151,000.00USD-54.24%
330,000.00USD-38.89%
540,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GT Biopharma Stock analysis

What does GT Biopharma do? GT Biopharma Inc, based in Brisbane, California, is a clinical-stage biopharmaceutical company operating in the Health Care sector. The company focuses on developing immuno-oncology therapeutics using its proprietary TriKE NK cell engager platform, which enhances natural killer cells to target cancer. It employs two full-time staff and is listed on the stock market since October 22, 2013. Its lead product, GTB-3550, is a tri-specific fusion protein for CD33-expressing cancers, currently in Phase 1 clinical trials. GT Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GT Biopharma stock

Current Liabilities of GT Biopharma is 2.32 M USD in 2025.

Current Liabilities of GT Biopharma changed from 7.70 M USD to 2.32 M USD, representing a -69.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities GT Biopharma since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's GT Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — GT Biopharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — GT Biopharma